The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Using Risk Scores to Link Molecular Mechanisms to Clinical Outcomes in Parkinson's Disease
Study Rationale:
The symptoms and course of Parkinson’s disease (PD) show remarkable variation from one person to another, indicating differences in the underlying disease process that may also be... -
Research Grant, 2017Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
Objective/Rationale:
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative... -
Research Grant, 2016Therapeutic Effects of XPro1595 on Motor and Non-motor Outcomes in a Pre-clinical Model of Parkinson's disease
Study Rationale:
Studies funded under the 2012 TDI award revealed that peripheral administration of XPro1595 in the 6-OHDA (neurotoxin) pre-clinical model afforded significant neuroprotection against... -
Research Grant, 2015Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease Supplement
Study Rationale:
STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in... -
Research Grant, 2014Role of LRRK2 in Dopamine Modulation of Striatal Glutamate Transmission
Objective/Rationale:
Many of the motor symptoms in Parkinson’s disease (PD) are attributed to a deficit of the neurotransmitter dopamine in the brain region called the striatum. Recent studies show... -
Dyskinesia Challenge, 2012Combined Therapy with Amantadine and Fenobam for Levodopa-induced Dyskinesia
Objective/Rationale:
Amantadine is currently the only available medication to treat levodopa-induced dyskinesia: involuntary, jerky movements caused by long-term use of the Parkinson’s drug levodopa...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.